Minireviews
Copyright ©The Author(s) 2024.
World J Gastroenterol. May 21, 2024; 30(19): 2512-2522
Published online May 21, 2024. doi: 10.3748/wjg.v30.i19.2512
Figure 2
Figure 2 Median overall survival shown in clinical trials by drugs approved as first-line systemic therapy, compared with sorafenib. IMbrave150 analyzed atezolizumab + bevalizumab. HIMALAYA investigated durvalumab + tremelimumab.